Sonim Technologies INC

DNA X, Inc. has filed an amendment to its Form 8-K to update disclosures regarding its equity position and its efforts to meet Nasdaq Capital Market continued listing requirements.

DNA X, Inc. filed an 8-K/A amendment to its previous filing, providing updated pro forma stockholders' equity figures to demonstrate compliance with Nasdaq's minimum equity requirement following a recent financing transaction.

DNA X, Inc. announced a $8.1 million private placement of Series B Convertible Preferred Stock, with $5 million in cash and $3.1 million from note cancellation, to fund working capital.

DNA X, Inc. has mutually agreed with Chardan Capital Markets LLC to terminate its $500 million common stock purchase agreement.

DNA X, Inc. has entered into a Securities Purchase Agreement to issue a convertible note, while simultaneously facing a potential delisting from the Nasdaq Capital Market.

DNA X, Inc. reports Q1 2026 financial results, highlighting the completion of its mobile asset sale and transition to an AI-driven crypto trading platform.

DNA X, Inc. reports Q1 2026 results following the divestiture of its legacy hardware business and transition to an AI-driven cryptocurrency trading platform.

Sonim Technologies reports increased quarterly net loss and significant cash burn, raising substantial doubt about its ability to continue as a going concern, while pursuing an asset sale and strategic alternatives.

Sonim Technologies reported an increased net loss for Q2 2025 and is pursuing a strategic asset sale and reverse merger to maximize stockholder value.

Sonim Technologies' Q1 2025 results show a slight revenue decrease but improved gross profit due to customer allowance expirations, alongside strategic expansion and new product launches.

Sonim Technologies experienced a significant revenue decrease in Q3 2024 due to a strategic shift away from white-label products, while launching new rugged devices and hotspots.

Sonim Technologies experienced a significant revenue decrease in Q2 2024 due to a strategic shift away from white-label products, while preparing for new product launches in the second half of the year.

DNA X, Inc. has completed the sale of its legacy phone and hotspot business and is now fully focused on its cryptocurrency trading platform, DNA X, while addressing going concern uncertainties.

Sonim Technologies files an amendment to its annual report on Form 10-K to include information typically found in the proxy statement, which will be filed later than expected, and to provide updated certifications from its principal executive and financial officers.

Sonim Technologies transitions from low-margin white label products, anticipates revenue growth in 2025 with new product launches, and focuses on expanding its rugged enterprise and public sector markets.

Sonim Technologies has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters.

Sonim Technologies reports a significant increase in revenue and a shift to near breakeven for fiscal year 2023, driven by new product launches and strategic market expansion.

DNA X, Inc.'s Chief Financial Officer, Clayton Crolius, was granted 35,000 restricted stock units vesting over one year.

DNA X, Inc.'s Acting CEO, Michael C. Mulica, was granted 50,000 restricted stock units, increasing his beneficial ownership.

Following Sonim Technologies Inc.'s recent offering of 7.4 million shares, director Laurence W. Lytton's beneficial ownership has fallen below the 10% threshold, as reported in a recent SEC Form 4 filing.

Laurence W. Lytton, a Director and 10% Owner of Sonim Technologies Inc., reported the sale of 866,916 shares of common stock across two transactions in late June 2025.

Laurence W. Lytton reports ceasing to beneficially own more than 10% of Sonim Technologies Inc.'s outstanding common stock due to a change in the number of shares outstanding.

Charles Becher, Chief Commercial Officer and General Manager of North America at Sonim Technologies, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Sonim Technologies is soliciting shareholder votes by December 29, 2025, on the proposed sale of its assets to Nexa (Social Mobile) and related proposals.

Sonim Technologies updates its proxy statement, revealing a strategic pivot to a DeFi business, a capital raise via a convertible note, and an increase in outstanding shares ahead of its Special Meeting.

Sonim Technologies, Inc. is selling its enterprise 5G solutions business for $15 million cash plus a potential $5 million earn-out, shifting focus to a new, undefined strategic transaction.

Sonim Technologies has filed a preliminary proxy statement for a special stockholder meeting to vote on the proposed $15 million asset sale to NEXA Mobility, with a potential $5 million earn-out.

Sonim Technologies, Inc. is seeking stockholder approval for a reverse stock split, an increase in authorized common shares, and an expansion of its equity incentive plan at a special meeting on October 16, 2025.

Sonim Technologies reported a 33% revenue decline in Q2 2025 to $11.2 million, alongside a net loss of $7.5 million, while advancing strategic initiatives including an asset sale agreement and new product launches.

Sonim Technologies has entered into a $500 million committed equity facility with Chardan Capital Markets and is selling its enterprise 5G solutions business for $15 million, while facing Nasdaq delisting concerns.

Sonim Technologies filed an S-1 registration statement for the resale of up to 350 million common shares by Chardan Capital Markets, linked to a new $500 million committed equity facility and a pending asset sale.

Sonim Technologies, a provider of rugged enterprise 5G solutions, has filed an S-1 registration statement to offer up to $10 million in common stock and pre-funded warrants, outlining its strategic expansion into new markets and product categories while addressing ongoing financial challenges and a proxy contest.

AJP Holding Company and Orbic North America have increased their non-binding offer to acquire substantially all of Sonim Technologies' assets to $25 million, while simultaneously launching a proxy contest to replace the current board, citing years of significant financial losses and shareholder dilution.

AJP Holding Company and Orbic North America have filed definitive proxy materials, urging Sonim Technologies stockholders to vote for their five board nominees at the upcoming July 18, 2025 Annual Meeting.

A group of significant shareholders, including AJP Holding Company and Orbic North America, has voluntarily discontinued their lawsuit against Sonim Technologies Inc. and its Board of Directors without prejudice.

Orbic North America, along with its affiliates, has submitted a revised non-binding proposal to acquire Sonim Technologies Inc. for $1.81 per share in cash, a 98.9% premium to Sonim's recent closing price, while criticizing Sonim's recent corporate actions.

A significant shareholder group, including AJP Holding Company and Orbic North America, has filed a lawsuit against Sonim Technologies Inc. and its board, alleging breach of fiduciary duties and improper rejection of director nominations aimed at entrenching current management.

A group of activist investors, including AJP Holding Company, LLC and Orbic North America, LLC, have filed an amended Schedule 13D to announce their intent to solicit proxies for the election of their director nominees to the Board of Sonim Technologies Inc. at the upcoming 2025 annual meeting.

Laurence W. Lytton has reported beneficial ownership of 100,521 shares, representing 6.8% of DNA X, Inc.'s common stock, as of June 30, 2026.

Laurence W. Lytton has reported beneficial ownership of 120,357 shares, representing 8.1% of the outstanding common stock of DNA X, Inc. as of April 21, 2026.

Laurence W. Lytton has reported a 9.96% beneficial ownership stake in DNA X, Inc.'s common stock as of December 31, 2025.

1 Main Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Sonim Technologies, Inc. as of December 31, 2025.

Streeterville Capital LLC and its affiliates have reported a complete divestment of their beneficial ownership in Sonim Technologies Inc., now holding 0% of the common stock.

Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, has reported a beneficial ownership of 9.98% in Sonim Technologies Inc. common stock.